UB Paderborn / Katalog / Suche / in CDI

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339

2020

Link zum Volltext

Verfügbarkeit prüfen

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1872-1882

2021

Link zum Volltext

Verfügbarkeit prüfen

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Advances in therapy, 2021-01, Vol.38 (1), p.350-365

2021

Link zum Volltext

Verfügbarkeit prüfen

Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia

British journal of nutrition, 2022-08, Vol.128 (4), p.604-612

2022

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure

International Journal of Endocrinology, 2015-01, Vol.2015, p.812610-9

2015

Link zum Volltext

Verfügbarkeit prüfen

607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A691-A691

2023

Link zum Volltext

Verfügbarkeit prüfen

Mobile phone use while driving-literary review

Transportation research. Part F, Traffic psychology and behaviour, 2017-05, Vol.47, p.132-142

2017

Link zum Volltext

Verfügbarkeit prüfen

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

JTO clinical and research reports, 2023-02, Vol.4 (2), p.100461-100461, Article 100461

2023

Link zum Volltext

Verfügbarkeit prüfen

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2

Future oncology (London, England), 2022-10, Vol.18 (33), p.3701-3711

2022

Link zum Volltext

Verfügbarkeit prüfen

Hypertension in Polycystic Ovary Syndrome: Novel Insights

Current hypertension reviews, 2020-01, Vol.16 (1), p.55

2020

Link zum Volltext

Verfügbarkeit prüfen

HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.289-289

2023

Link zum Volltext

Verfügbarkeit prüfen

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies

Clinical lung cancer, 2021-09, Vol.22 (5), p.449-460

2021

Link zum Volltext

Verfügbarkeit prüfen

Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome

European journal of endocrinology, 2016-12, Vol.175 (6), p.551

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity

Journal of medical biochemistry, 2018-12, Vol.37 (4), p.476-485

2018

Link zum Volltext

Verfügbarkeit prüfen

Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.12096-12096

2020

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21542-e21542

2020

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e15003-e15003

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT107: A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT107-CT107

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-17-02: ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-17-02

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessment of age-related influences on the quality of life of breast cancer patients before and after surgical treatment

Vojnosanitetski pregled, 2020, Vol.77 (9), p.908-916

2020

Link zum Volltext

Verfügbarkeit prüfen

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA9005-LBA9005

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase III safety evaluation of intravenous NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron, over multiple cycles

Journal of clinical oncology, 2017-11, Vol.35 (31_suppl), p.122-122

2017

Link zum Volltext

Verfügbarkeit prüfen

HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e16065-e16065

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia

Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure

607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

Mobile phone use while driving-literary review

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2

Hypertension in Polycystic Ovary Syndrome: Novel Insights

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies

Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome

Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity

Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer

Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study

Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis

Abstract CT107: A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION

Abstract P1-17-02: ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer

Assessment of age-related influences on the quality of life of breast cancer patients before and after surgical treatment

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study

Phase III safety evaluation of intravenous NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron, over multiple cycles

HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

Suchergebnisse filtern